Literature DB >> 21722786

Claudication: treatment options for femoropopliteal disease.

Martin Schillinger1, Erich Minar.   

Abstract

Intermittent claudication due to chronic femoropopliteal obstruction is a common disease, and patients are potentially severely disabled by the painful limitation of walking capacity. Despite major advances in pharmacological therapy of atherosclerosis, effective medication specifically for treatment of intermittent claudication is still not available. Training programs work well for patients with mild to moderate symptoms but frequently fail in patients with very compromised walking capacity. Patients with severe symptoms and markedly reduced quality of life therefore are candidates for revascularization. The preferred method of revascularization is endovascular treatment; this includes simple balloon angioplasty, debulking techniques, stent implantation, and, more recently, drug eluting technologies. Selected patients are candidates for surgery which encompasses endarterectomy of focal common femoral lesions as well as femoropopliteal bypass surgery in patients with very extensive disease or after failed endovascular approaches. The following article reviews current aspects of the management of femoropopliteal disease in patients with intermittent claudication.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722786     DOI: 10.1016/j.pcad.2011.04.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  4 in total

Review 1.  An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2013-03

Review 2.  Endovascular treatment of femoro-popliteal lesions.

Authors:  Aman Kansal; Chandler A Long; Manesh R Patel; W Schuyler Jones
Journal:  Clin Cardiol       Date:  2018-12-04       Impact factor: 2.882

3.  ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.

Authors:  Ilka Ott; Salvatore Cassese; Philipp Groha; Birgit Steppich; Felix Voll; Martin Hadamitzky; Tareq Ibrahim; Sebastian Kufner; Karl Dewitz; Theresa Wittmann; Albert Markus Kasel; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati; Massimiliano Fusaro
Journal:  J Am Heart Assoc       Date:  2017-07-25       Impact factor: 5.501

4.  Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis.

Authors:  Hai Feng; Xueming Chen; Xiaobo Guo; Zhe Zhang; Zhiwen Zhang; Bin Liu; Lishan Lian
Journal:  BMC Cardiovasc Disord       Date:  2020-08-31       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.